31 reports

In addition, the development of drugs for genetic obesity is one of the key trends in the market and will likely impact the market growth.

  • Depression
  • Allergan plc
  • Eli Lilly & Co.
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited

This may be related to genetic predisposition, chronic stress, or illness, certain medications etc.

  • Depression
  • World
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • 1.2 TYPES
  • TYPES OF DEPRESSION

There are traces showing that depression runs in families, suggesting a genetic link.

  • Depression
  • World
  • AstraZeneca PLC
  • Lundbeck Inc.
  • Pfizer Inc.
  • MHDS - MARKET SIZE AND FORECAST 2017-2022

AD is one of the most common types of NDDs.

  • Depression
  • Eli Lilly & Co.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • 3.1 ETIOLOGY AND PATHOPHYSIOLOGY
  • 4.1 DISEASE BACKGROUND

Saying a patient with this profile or genetic makeup, he will benefit from a drug type A, B, or C.

  • Depression
  • Alkermes plc
  • Allergan plc
  • Lundbeck Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Changes in lifestyle
  • 07. Disorder Overview

Major depressive disorder is mostly caused by psychological, biological, genetic, and social factors.

  • Depression
  • Actavis plc
  • Bristol-Myers Squibb Company
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • Executive Summary
  • 7MM, 12-MONTH TOTAL PREVALENT CASES OF MDD,

Psychiatry; ##(##): ##-##.

  • Depression
  • Japan
  • United States
  • World
  • Forecast
  • 07.1 TYPES OF DEPRESSION
  • 11. Market Growth Drivers

Major depressive disorder is mostly caused by psychological, biological, genetic, and social factors.

  • Depression
  • United States
  • Actavis plc
  • Eli Lilly & Co.
  • GlaxoSmithKline plc

To raise this finance, the company issued equity securities for one investor.

  • Depression
  • Pharmaceutical
  • United States
  • Company
  • RespireRx Pharmaceuticals Inc.
  • Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders
  • Aug 02, 2017: 23andMe Enrolling For First-of-its-Kind Study on Major Depressive and Bipolar Disorders

The company offers raw genetic data and ancestry-related genetic reports.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Lundbeck Inc.
  • Global Markets Direct Report Coverage

The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are ##, ##, ##, ## and ## respectively.

  • Depression
  • Therapy
  • United States
  • World
  • Product Initiative

There was one serious adverse event (confusion) reported in one of the two patients who received oral solution.

  • Depression
  • United States
  • Company
  • Company Operations
  • SAGE Therapeutics
  • R&D Progress
  • R&D Progress

Decreased SLC##A## expression, due to genetic or environmental factors, might alter neuronal circuits related to the susceptibility of disease.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.
  • Global Markets Direct Report Coverage

The molecules developed by companies in Pre-Registration, Phase III, Phase II and Preclinical stages are ##, ##, ## and ## respectively.

  • Depression
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative
  • R&D Progress
  • SMALL MOLECULE TO INHIBIT FKBP51 FOR ANXIETY AND MAJOR DEPRESSIVE DISORDER - DRUG PROFILE

He was also formerly associate medical director of discovery research at Shire Human Genetic Therapies.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Anavex Life Sciences Corp.

Celsis will also determine genetic variations in VistaGen' s pluripotent stem cell lines that are important to drug development.

  • Depression
  • Therapy
  • United States
  • Litigation And Patent
  • VistaGen Therapeutics, Inc.

Celsis will also determine genetic variations in VistaGen' s pluripotent stem cell lines that are important to drug development.

  • Depression
  • Therapy
  • United States
  • Company
  • VistaGen Therapeutics, Inc.

More recently, the group found a genetic basis for those eye movements.

  • Depression
  • Healthcare
  • United States
  • Deals & Alliance
  • GlobalData's company

There was one serious adverse event (confusion) reported in one of the two patients who received oral solution.

  • Depression
  • Therapy
  • United States
  • Company Financials
  • SAGE Therapeutics
  • Introduction

This includes data from multiple genetically modified rodent models where reduction in NR##B expression impairs cognitive performance and increases in NR##B expression improve cognitive performance.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.

University of Utah undertakes research on animal subjects, radiation and laboratory safety, resource for genetic and epidemiologic research, and others.

  • Clinical Trial
  • Depression
  • Mental Health
  • Therapy
  • GlobalData's company

The molecules developed by companies in Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ## and ## respectively.

  • Depression
  • Pathology
  • Therapy
  • United States
  • Product Initiative
  • ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) - PIPELINE BY P2D BIOSCIENCE
  • DEPRESSION - PIPELINE BY BOEHRINGER INGELHEIM GMBH

Oct ##, 2016: Medgenics Presents New Data Showing Prevalence of Genetic Mutations in Pediatric Populations with Attention Deficit Hyperactivity Disorder Medgenics, Inc.

  • Depression
  • Psychotic Disorder
  • United States
  • Company
  • Product Initiative
  • SMALL MOLECULE TO TARGET SLC6A15 FOR MAJOR DEPRESSIVE DISORDER AND ANXIETY DISORDERS - DRUG PROFILE
  • MIR-135 - DRUG PROFILE

The Company also reported that, in a genetic model of type ## diabetes (db/ db mouse), NSI-## treatment showed significant reversal in all of the same indices of neuropathy.

  • Depression
  • United States
  • Company
  • Product Initiative
  • Allergan plc
  • SAGE-217 - DRUG PROFILE

It was also under development as an intravenous therapy for refractory status epilepticus (RSE) and as an oral therapy for orphan genetic epilepsy disorders, such as Dravet syndrome, Rett syndrome and Fragile X syndromes.

  • Depression
  • Sleep Aid
  • United States
  • World
  • Product Initiative

The molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Depression
  • Therapy
  • United States
  • Product Initiative
  • NeurOp, Inc.

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Bipolar Disorder
  • Depression
  • United States
  • Product Initiative
  • Intra-Cellular Therapies, Inc.
  • 3. GDCT ID IS THE UNIQUE ID OF GLOBALDATA'S PHARMA INTELLIGENCE CENTER CLINICAL TRIAL DATABASE

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Bipolar Disorder
  • Clinical Trial
  • Depression
  • Neurology
  • World

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Bipolar Disorder
  • Depression
  • Research And Development
  • United States
  • Company Operations
  • Drug Profiles

Decreased SLC##A## expression, due to genetic or environmental factors, might alter neuronal circuits related to the susceptibility of disease.

  • Depression
  • United States
  • Company Operations
  • Product Initiative
  • Allergan plc